Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 1, Issue 1, 2001, Pages 77-84

  Bos, Jasper M ^a   de Jong van den Berg, Lolkje T W ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Combination antiretroviral therapy; Combination HIV therapy; Cost ( ) effectiveness; Cost utility; Economic evaluation; HAART; Highly active antiretroviral therapy; Pharmacoeconomics

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ECONOMIC ASPECT; ECONOMIC EVALUATION; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; METHODOLOGY; MORTALITY; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; REVIEW; TECHNOLOGY;

EID: 0035556579     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.1.1.77     Document Type: Review

References (41)

1. The impact of antiviral therapy on HIV disease
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Changing patterns of mortality across Europe in patients infected with HIV-1
4. Hit HIV-1 hard but only when necessary
5. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
6. Costs of medical care in the era of highly active antiretroviral therapy
7. The care of HIV-infected adults in the United States
8. Helping the urban poor stay with antiretroviral HIV drug therapy
9. Cost effectiveness of combination HIV therapy: 3 years later
10. Valuing healthcare. Costs, benefits and effectiveness pharmaceuticals and other medical technologies
11. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US
12. An evaluation of the cost-effectiveness of adding lamivudine to zidovudine containing regimes in HIV infection, Canadian perspective
13. A prospective evaluation of the cost-effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimes in HIV infection. European Perspective
14. Long-term impact of highly active antiretroviral therapy on hiv-related healthcare costs
15. Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs
16. Advances in antiretroviral therapy and viral load monitoring
17. Framing and designing the cost-effectiveness analysis
18. Antiretroviral therapy for HIV infection
19. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center
20. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy
21. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy
22. Effect of highly active antiretroviral therapy on outcomes in Veterans Affairs Medical Centres
23. Effect of HAART on health status and hospital costs of severe HIV-infected patients: A modelling approach
24. The impact of new antiretroic therapeutic schemes on the cost for AIDS treatment in Greece
25. The cost effectiveness of combination antiretroviral therapy for HIV disease
26. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study
27. Combination antiretroviral therapy in HIV infection. An economic perspective
28. The changing economics of HIV care
29. Assessing the cost-effectiveness of highly active antiretroviral therapy for adults with HIV in England
30. Combined antiviral treatment in HIV infection. Is it value for money?
31. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection
32. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-effectiveness in health and medicine
33. Recommendations of the Panel on Cost-effectiveness in Health and Medicine
34. Recommendations for reporting cost-effectiveness analyses
35. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee, including economic analyses
36. Richtlijnen voor farmaco-economisch onderzoek
37. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events
38. Cost and financing aspects of antiretroviral therapy
39. Estimating the national cost of treating people with HIV disease: Patient, payer and provider data